Sanofi Global Health Unit: first deliveries of cardio-metabolic products under the Impact brand to the Republic of Djibouti and to global non-governmental organizations
The Sanofi Global Health Unit (GHU) carries a portfolio of 30 Sanofi medicines deemed essential by the WHO and aims to deliver affordable quality care to patients in 40 of the world’s poorest countries. In July 2022, Sanofi Global Health announced the launch of Impact, a new brand produced by Sanofi dedicated to non-profit distribution to vulnerable populations in the GHU’s scope. It also aims to combat the use of counterfeit and substandard medicines. The brand leverages single pack technology with an integrated QR code, to provide product information in local languages and ensure both, affordability and wide availability.
In September 2023, the Sanofi Global Health Unit has made the first deliveries of its non-profit Impact brand to the Republic of Djibouti and to global non-governmental organizations. The first products sold under the Impact brand are the Insulin Glargine Impact SoloStar® pens, an analogue insulin in a device convenient for diabetic patients, and Enoxaparin Sodium Impact®, a medication indicated for the treatment of deep vein thrombosis, an often-underdiagnosed condition in Djibouti and other African countries. By the end of the year at least three more products should be made available, offering more options to patients living with non-communicable diseases in low-and-middle-income countries.
Since the launch of Sanofi Global Health Unit, 361,625 non-communicable disease (NCD) patients have been treated and 29 countries have been activated. The Sanofi GHU’s objective is to reach 1.5 million NCD patients by 2026 (cumulative since 2022).
